Related Experiment Video
Updated: Dec 31, 2025
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
A Multifunction Lipid-Based CRISPR-Cas13a Genetic Circuit Delivery System for Bladder Cancer Gene Therapy
Jing Fan1,2,3, Yuchen Liu1, Lisa Liu1
1Department of Urology, Shenzhen Second People's Hospital , The First Affiliated Hospital of Shenzhen University , Shenzhen 518039 , China.
Abstract:
The treatment of bladder cancer has recently shown minimal progress. Gene therapy mediated by CRISPR provides a new option for bladder cancer treatment. In this study, we developed a versatile liposome system to deliver the CRISPR-Cas13a gene circuits into bladder cancer cells. After in vitro studies and intravesical perfusion studies in mice, this system showed five advantages: (1) CRISPR-Cas13a, a transcriptional targeting and cleavage tool for gene expression editing, did not affect the stability of the cell genome; (2) the prepared liposome systems were targeted to hVEGFR2, which is always highly expressed in bladder cancer cells; (3) the CRISPR-Cas13a sequence was driven by an artificial tumor specific promoter to achieve further targeting; (4) a near-infrared photosensitizer released using near-infrared light was introduced to control the delivery system; and (5) the plasmids were constructed with three crRNA tandem sequences to achieve multiple targeting and wider therapeutic results. This tumor cell targeting lipid delivery system with near-infrared laser-controlled ability provided a versatile strategy for CRISPR-Cas13a based gene therapy of bladder cancer.
Insights
This study introduces a novel liposome system for CRISPR-Cas13a gene therapy in bladder cancer. The system targets tumor cells, offers controlled gene editing, and enhances therapeutic outcomes for bladder cancer treatment.
Area of Science:
- Oncology
- Gene Therapy
- Nanotechnology
Background:
- Bladder cancer treatment options are limited, necessitating novel therapeutic strategies.
- Gene therapy, particularly using CRISPR-Cas13a, presents a promising avenue for targeted cancer treatment.
Purpose of the Study:
- To develop and evaluate a versatile liposome delivery system for CRISPR-Cas13a gene circuits in bladder cancer.
- To assess the efficacy and safety of this system for targeted gene editing in bladder cancer cells.
Main Methods:
- Development of a liposome system for CRISPR-Cas13a gene delivery.
- In vitro studies and intravesical perfusion studies in mice.
- Incorporation of hVEGFR2 targeting, tumor-specific promoters, near-infrared photosensitizers, and multiple crRNA sequences.
Main Results:
- CRISPR-Cas13a demonstrated gene expression editing without compromising genome stability.
- Liposomes effectively targeted hVEGFR2-expressing bladder cancer cells.
- Near-infrared light controlled the release of the photosensitizer for targeted delivery.
- Multi-crRNA sequences enabled broader therapeutic effects.
Conclusions:
- The developed liposome system offers a versatile strategy for CRISPR-Cas13a-based gene therapy in bladder cancer.
- This approach combines targeted delivery, controlled gene editing, and enhanced therapeutic potential.
Related Concept Videos
01:28CRISPR/Cas9 Genome Editing
01:59CRISPR